Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) will release fourth-quarter and year-end 2025 financial results after market close on Wednesday, February 11, 2026. A conference call to discuss results and corporate updates begins at 4:30 p.m. ET the same day.
Investors can join by phone or listen via webcast at the company's Webcasts page; a telephone replay is available through February 18, 2026 and the webcast archive will remain on the site for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VKTX gained 0.51%, reflecting a mild positive market reaction. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 36 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $3.01B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VKTX fell 1.7% while close biotech peers were mixed: IMVT down 1.04%, but XENE, CRNX, SLNO and SRRK up between 0.65% and 2.93%, suggesting stock-specific dynamics rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Phase 2 data | Positive | -0.7% | VENTURE Phase 2 VK2735 obesity data published with up to 14.7% weight loss. |
| Jan 08 | Clinical trial update | Positive | -2.3% | Completion of enrollment in VK2735 Phase 1 maintenance dosing obesity study. |
| Jan 07 | Executive appointment | Positive | +0.3% | Appointment of chief commercial officer to lead VK2735 commercialization strategy. |
| Jan 05 | Conference appearance | Neutral | +0.5% | Announcement of corporate presentation at the J.P. Morgan Healthcare Conference. |
| Nov 19 | Phase 3 enrollment | Positive | -4.6% | Early, above-target completion of enrollment in Phase 3 VANQUISH-1 VK2735 trial. |
Recent clinically positive VK2735 updates often coincided with negative next-day moves, while corporate/meeting news saw mild gains.
Over the last few months, VKTX news has centered on obesity candidate VK2735 and corporate positioning. Multiple Phase 2 and Phase 3 updates, including VANQUISH-1 enrollment completion and VENTURE results publication, reported substantial weight-loss data and trial progress but were followed by share declines of up to 4.56%. In contrast, management changes and investor conference participation around January 2026 produced small positive reactions, highlighting mixed trading responses to otherwise constructive developments.
Market Pulse Summary
This announcement schedules Viking’s Q4 and year-end 2025 results and conference call for February 11, 2026, giving a clear timeline for the next financial and corporate update. In the months leading up to this, the company highlighted key VK2735 obesity trial milestones and management additions, with mixed share-price reactions. Investors may focus on cash use, trial progress, and any updated commentary on the Phase 3 VANQUISH program during the upcoming call.
AI-generated analysis. Not financial advice.
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, February 11, 2026. To participate on the conference call, please dial (844) 850-0543 from the
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2025-on-february-11-2026-302678194.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) report Q4 and year-end 2025 financial results?
How can investors join the Viking (VKTX) conference call on February 11, 2026?
Will there be a replay of the Viking Therapeutics (VKTX) February 11, 2026 conference call?
Where can I watch the live webcast and archived replay for Viking Therapeutics (VKTX)?
What topics will Viking Therapeutics (VKTX) cover on the February 11, 2026 call?
What phone numbers does Viking Therapeutics (VKTX) provide for the February 11, 2026 call?
